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Abstract
Placebo response in clinical trials of antidepressant medications is substantial and increasing. High
placebo response rates hamper efforts to detect signals of efficacy for new antidepressant
medications, contributing to more failed trials and delaying the delivery of new treatments to
market. Media reports seize upon increasing placebo response and modest advantages for active
drugs as reasons to question the value of antidepressant medication, which may further stigmatize
treatments for depression and dissuade patients from accessing mental health care. Conversely,
enhancing the factors responsible for placebo response may represent a strategy for improving
available treatments for Major Depressive Disorder. A conceptual framework describing the
causes of placebo response is needed in order to develop strategies for minimizing placebo
response in clinical trials, maximizing placebo response in clinical practice, and talking with
depressed patients about the risks and benefits of antidepressant medications. This review
examines contributors to placebo response in antidepressant clinical trials and proposes an
explanatory model. Research aimed at reducing placebo response should focus on limiting patient
expectancy and the intensity of therapeutic contact in antidepressant clinical trials, while the
optimal strategy in clinical practice may be to combine active medication with a presentation and
level of therapeutic contact that enhances treatment response.
Introduction
Placebo response in antidepressant clinical trials has recently captured the attention of
psychiatric researchers, clinicians, and the lay public. Scientific interest focuses on the
influence of placebo response on signal detection in clinical trials and what its physiologic
mechanisms reveal about the pathophysiology of Major Depressive Disorder. The public
would like to know whether responses to antidepressants are caused by specific effects of
the medications or are “just” placebo effects. Clinicians may alternately view placebo
response as a challenge to their decisions to prescribe antidepressant medication and a
potential tool to improve patient care. Complicating much of this discourse has been a
murky understanding of what contributes to placebo response in clinical trials. This review
presents a model of placebo response in order to aid in the interpretation of randomized
controlled trial results to clinical practice, set an agenda for future research, and help
clinicians speak with their patients about antidepressant treatments.
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The Problem and the Promise of Rising Placebo Response
In antidepressant trials for adults, placebo response averages 31% compared to a mean
medication response of 50%, and it has risen at a rate of 7% per decade over the past 30
years (1). Children and adolescents with Major Depressive Disorder exhibit even higher
rates of placebo response (mean of 46% compared to a mean medication response of 59%)
that have also been increasing over time (2). High placebo response reduces medication-
placebo differences and leads investigators to make methodological modifications (i.e., the
use of multiple study sites to increase sample size) that increase measurement error, both of
which make it more difficult to demonstrate a statistically significant benefit of a putative
antidepressant agent over placebo. Consequently, the average difference observed in
published antidepressant trials between medication and placebo has decreased from an
average of 6 points on the Hamilton Rating Scale for Depression (HAM-D) scale in 1982 to
3 points in 2008 (3). For most currently approved antidepressants, less than half of the
efficacy trials filed with the Food and Drug Administration for regulatory approval found
active drug superior to placebo (4–5). While not all trials failing to distinguish medication
from placebo represent false negatives, meta-analyses of antidepressant trials suggest that
high placebo response rather than low medication response explains most of the variability
in drug-placebo differences (2). The increasing number of failed trials in recent years has
made developing psychiatric medications progressively more time-consuming (average of
13 years to develop a new medication) and expensive (estimates range from $800 million to
$3 billion per new agent) compared to medications for non-CNS indications (6). These
considerations contributed to recent decisions by several large pharmaceutical companies to
reduce or discontinue research and development on medications for brain disorders,
prompting warnings of “psychopharmacology in crisis” (7).
From a different perspective, enhancing the therapeutic components leading to placebo
response may be a way of improving the clinical treatment of patients with depression.
Major Depressive Disorder affects approximately 120 million people worldwide (including
nearly 15 million American adults each year) and is a leading cause of disability due to
illness (8). With currently available treatments, many patients will not experience sustained
remission of their depression (9). As described further below, treatment with antidepressant
medication involves much more than simply dispensing a pill: an expectation of
improvement is instilled in patients receiving treatment, and they are exposed to a health
care environment that has many supportive and therapeutic features. These non-
pharmacologic aspects of clinical management likely cause a substantial portion of observed
medication and placebo response in clinical trials (10), yet they are typically not provided to
the same extent in standard clinical practice. Whereas it was once believed that the
therapeutic effects of expectancy and contact with health care staff were transient, more
recent data show that 75% of placebo responders stay well during the continuation phase of
treatment (11). Thus, optimizing the therapeutic components leading to placebo response has
the potential to significantly improve treatment outcomes in clinical practice.
Differentiating the Placebo Effect from Placebo Response
“Placebo response” can be defined as the change in symptoms occurring during a clinical
trial in patients randomized to receive placebo. Placebo response, which is directly observed
and quantified in a research study, is often conflated with the term placebo effect. A
“placebo effect” can be defined as the therapeutic effect of receiving a substance or
undergoing a procedure that is not caused by any inherent powers of the substance or
procedure (12). For example, an inert cream has no “inherent powers” to relieve pain, but
being informed the cream is an analgesic may result in a person feeling less pain when a
painful stimulus is applied because the expectation of pain relief causes the release of
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endogenous opiates in the brain. While placebo effects are one contributor to the placebo
response observed in a research study, there are many other factors that may also influence
placebo response.
To clarify this differentiation further, the sources of symptom change in antidepressant
clinical trials can be grouped into categories, which are depicted in Figure 1. Treatment
factors comprise all the interventions and study procedures experienced by a patient in a
clinical trial. Taking a pill believed to be an effective treatment for depression may generate
a placebo effect (based on increased expectancy of improvement), while supportive contacts
with study clinicians and undergoing medical procedures may also have therapeutic
elements. Expectancy-based placebo effects and effects of the therapeutic setting may be
moderated by demographic and clinical characteristics of participating patients.
Measurement factors represent sources of bias and error inherent in measuring depressive
symptoms, and natural history factors reflect spontaneous improvement and worsening in
the patient’s condition that is unrelated to the study procedures. The symptom change
observed in patient receiving placebo in a clinical trial (i.e., placebo response) is caused by
the sum effects of these factors and their interactions. While large placebo effects may lead
to large observed placebo response, it is also possible that high placebo response could be
observed even where there are minimal placebo effects operative (i.e., if there has been
substantial improvement resulting from the therapeutic setting, regression to the mean, rater
bias, or spontaneous fluctuation in illness severity).
Treatment Factors Contributing to Placebo Response
Expectancy-based placebo effects
Two theoretical approaches to understanding the mechanisms of placebo effects have been
expectancy theory and classical conditioning (12). Expectancy theory postulates that placebo
treatments instill a (conscious) positive expectation of improvement in the patient that
actually causes the change in a patient’s symptoms. Conditioning theorists hold that placebo
responses represent a type of non-conscious learning in which an individual associates
improvement in symptoms (unconditioned response) with neutral stimuli such as pills,
health care providers, or procedures (conditioned stimulus) that themselves become capable
of eliciting an effect (conditioned response). In general, both conscious expectancy and non-
conscious conditioning mechanisms likely contribute to the placebo effects observed in
pharmacologic studies. However, given the importance of verbal information in shaping
placebo effects and the fact that substantial placebo effects are observed in treatment-naïve
patients, most empirical studies of the mechanisms of placebo effects in antidepressant
clinical trials have focused on patient expectancy.
Khan et al (2004) first reported that the number of treatment arms in a study was negatively
correlated with the “success” of the trial (defined as finding a significant difference between
drug and placebo) (13). A greater number of treatment arms increases the probability of
receiving active medication, which may increase patient expectations and generate higher
placebo response. The influence of patient expectancy on antidepressant response also has
been observed in comparisons of medication response between placebo-controlled trials
(i.e., one or more medications compared to placebo) and active comparator trials (i.e., one or
more medications with no placebo group). In adults and older adults with Major Depressive
Disorder, mean medication response rates in comparator trials are significantly greater than
the mean medication response rates in placebo-controlled trials (14–15). Patients in
comparator trials know they have a 100% chance of receiving an active medication, which
may increase their expectancy of improvement, leading to enhanced placebo effects and
greater observed antidepressant response.
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Consistent with these results, Papakostas and Fava (2009) reported that the probability of
receiving placebo in a clinical trial was negatively correlated with antidepressant and
placebo response (16). For each 10% decrease in the probability of receiving placebo, the
probability of antidepressant response increased 1.8% and the probability of placebo
response increased 2.6%. Similarly, Sinyor et al (2010) evaluated 90 randomized controlled
trials of antidepressant medications for unipolar depression, comparing response and
remission rates between trials comparing medication to placebo (drug-placebo), two
medications to placebo (drug-drug-placebo), and one medication to another (drug-drug)
(17). They found that medication response was significantly higher in drug-drug studies
(65.4%) compared to drug-drug-placebo studies (57.7%) and drug-placebo studies (51.7%)
(p < 0.0001). Response to placebo in placebo-controlled trials was significantly higher in
drug-drug-placebo studies compared to drug-placebo studies (46.7% vs. 32.2%,
respectively, p = 0.002).
The meta-analytic results suggest that the design of a clinical trial shapes patients’
expectancies of improvement during the trial, which in turn influence response to
antidepressant medication and placebo. However, the veracity of this interpretation must be
tested in studies which directly measure patient expectancy in different types of
antidepressant clinical trials and determine the relation of expectancy to treatment outcome.
Two studies measuring patient expectancy at baseline reported that higher expectancy
predicts greater symptom improvement during treatment of depression with antidepressant
medication (18–19). Moreover, a recent pilot study experimentally manipulated expectancy
in subjects with Major Depressive Disorder by randomizing 43 adult outpatients to placebo-
controlled (i.e., 50% chance of receiving active drug) or comparator (i.e., 100% chance of
receiving active drug) administration of antidepressant medication (20). Randomization to
the comparator condition resulted in significantly increased patient expectancy relative to
the placebo-controlled arm of the study (t = 2.60, df 27, p = 0.015). Among patients
receiving medication, a trend was observed for higher pre-treatment expectancy of
improvement to be positively correlated with the change in depressive symptoms observed
over the study (r = 0.44, p = 0.058). The manipulation of expectancy in this study permits
the causal inference to be made that more positive expectancy leads to greater improvement
in depressive symptoms, both within a single type of clinical trial and between different trial
types.
In summary, the consent procedure for pharmacotherapy trials, in which prospective
participants become aware of the study design, the past effectiveness of the drugs and
placebos used in the study, and the investigator’s opinions of the treatment options,
influences patients’ expectancies of how participation in a clinical trial will affect their
depressive symptoms. Expectancy appears to be a primary mechanism of placebo effects
and significantly influences both observed placebo response as well as antidepressant
medication response. In both treatment groups, patients are receiving a pill that they believe
may represent a treatment for their condition.
Therapeutic setting
Since the ability to generate treatment expectancies requires relatively advanced cognitive
capacities, it is puzzling to observe high placebo response in children with depression.
Compared to adults, participants in pediatric Major Depressive Disorder trials are less
cognitively equipped to understand the nature of the study in which they are participating,
and they actually receive less information at the time of their enrollment into the study
(since their parents provide informed consent). To evaluate the significance of expectancy
effects in younger patients, Rutherford et al (2011) analyzed antidepressant response
between comparator and placebo-controlled studies of antidepressants for children and
adolescents with depressive disorders (21). Contrary to the large differences observed
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between these study types in adults and older adults with depression, there was no
significant difference in medication response between comparator and placebo-controlled
studies enrolling children and adolescents.
Rather than patient expectancy, what appeared to influence treatment response was the
amount of therapeutic contact patients received: adolescents experienced greater placebo
response as the number of study visits increased. In an antidepressant clinical trial, patients
experiencing social isolation and decreased activity levels as part of their depressive illness
enter a behaviorally activating and interpersonally rich new environment. They interact with
research coordinators and medical staff, receive lengthy clinical evaluations by highly
trained professionals, and are provided with diagnoses and psycho-education that explain
their symptoms. Medical procedures are performed, such as blood tests, electrocardiograms,
and vital sign measurements. Finally, clinicians meet with patients weekly to listen to their
experiences and facilitate compliance by instilling faith in the effectiveness of treatment.
Considerable empirical evidence supports the therapeutic effectiveness of these
interventions. Optimistic or enthusiastic physician attitudes, as compared to neutral or
pessimistic attitudes, are associated with greater clinical improvements in medical
conditions as diverse as pain, hypertension, and obesity (22). A therapeutic relationship in
which clinicians provide patients with a clear diagnosis, give them opportunity for
communication, and agree on the problem has been shown to produce faster recovery (23).
In addition, physical aspects of the treatment such as the pill dosing regimen, the color of
pills, and the technological sophistication of the treatment procedures can influence
treatment response (24).
Posternak and Zimmerman (2007) investigated the influence of therapeutic contact
frequency on antidepressant and placebo response in 41 RCTs of antidepressants for MDD
(25). These investigators calculated the change in HRSD scores observed over the first 6
weeks of treatment in patients assigned to antidepressant medication and placebo,
comparing studies having 6 weekly assessments (weeks 1–6) to those having 5 (weeks 1–4
and 6) and 4 (weeks 1–2, 4, and 6) assessments. Participants treated with placebo who
returned for a week 3 visit experienced 0.86 greater reduction in HRSD scores between
weeks 2 and 4 compared to those who did not, while participants having a week 5 visit had
0.67 greater reduction in HRSD scores between weeks 4 and 6 compared to those who did
not. A cumulative therapeutic effect of additional follow up visits on placebo response was
found: between weeks 2 and 6, patients with weekly visits improved 4.24 HRSD points,
while those with 1 fewer visit improved 3.33 points and those with 2 fewer visits improved
2.49 points. Thus, the presence of additional follow up visits appeared to explain
approximately 50% of the symptom change observed between weeks 2 and 6 among patients
receiving placebo. Participants receiving active medication also experienced more
symptomatic change with increased numbers of follow-up visits, but the relative effect of
this increased therapeutic contact was approximately 50% less than that observed in the
placebo group.
The intensive therapeutic contact found in clinical trials may be contrasted with what
patients being treated with antidepressants receive in the community. In community samples
of patients receiving antidepressant medication, 73.6% are treated exclusively by their
general medical provider as opposed to a psychiatrist (26). Fewer than 20% of patients have
a mental health care visit in the first 4 weeks after starting an antidepressant (27), and fewer
than 5% of adults beginning treatment with antidepressant medications have as many as 7
physician visits in their first 12 weeks on the medication (28). Thus, assignment to placebo
in an antidepressant clinical trial represents an intensive form of clinical management that
has therapeutic effects.
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Methods of controlling for expectancy and the therapeutic setting in clinical trials
Greater patient expectancy and therapeutic effects of the health care setting lead to increased
placebo response and, to a lesser degree, increased medication response. A ceiling is placed
on potential medication response by the relatively constant proportion of the sample who
will not respond to treatment (due to diagnostic misclassification, treatment refractoriness,
etc.). Since increased placebo response thereby decreases medication-placebo differences,
investigators have sought to identify methods of minimizing placebo response (and the
component of medication response caused by placebo response) as a means of improving
signal detection in clinical trials. One strategy for dealing with expectancy-based placebo
effects and therapeutic responses to the health care setting has been to conduct single-blind
lead-in periods aimed at identifying and excluding participants whose symptoms respond
quickly to placebo. Multiple analyses have determined that such lead-ins have not been
effective in reducing placebo response or improving detection of drug-placebo differences
(21, 29–30). However, one study suggests that double-blind lead-in periods, in which study
personnel are also blinded to the duration of placebo lead-in, may be more effective (31).
Measurement Factors Contributing to Placebo Response
In most clinical trials, investigators assess change in the severity of patient’s depressive
illness based on symptom changes that are self-reported by patients or elicited by trained
raters. Measurements of depressive symptoms are subject to random error like any other
measurement, but unlike more objective measurements, such as serum cholesterol or blood
pressure, depression symptom severity scores also may be subject to additional sources of
bias. Conceptually, one can distinguish cases in which a patient’s depression score
decreased because his depressive illness actually improved from cases in which the score
changed for other reasons.
Regression to the mean
One source of apparent symptom change in antidepressant trials is regression to the mean,
which is a statistical phenomenon occurring when repeated measurements associated with
random error are made on the same subject over time (32). To illustrate, one can imagine
that if an individual with a “true” Hamilton Rating Scale for Depression (HAM-D) score of
10 underwent repeated ratings, a normal distribution with a mean of 10 would be obtained
due to random error in measurement. If the initial value obtained happened to be unusually
high or low, then the next observed value likely would be closer to the subject’s true mean
score of 10 based on chance alone. Regression to the mean poses a problem at the group
level in clinical trials, because a threshold depression severity score is set as an inclusion
criterion (e.g., HAM-D > 16). Some of the individuals included in the study actually have
true means below 16, and the tendency for the depression scores of these subjects to
decrease on repeated measurement will give the appearance of group-level improvement
when in fact no true change has occurred. This decrease in mean HAM-D scores will not be
offset by a corresponding “upward” regression to the mean in those individuals whose
HAM-D scores were initially underestimated, because these individuals will have been
excluded from participation in the study.
Sources of bias
Rater bias occurs when an individual’s rating of symptom severity in an antidepressant
clinical trial is influenced by underlying beliefs or motivations with respect to the treatments
under study (33). For example, clinical raters typically perceive more symptom change in
response to treatment than is self-reported by patients, possibly reflecting an excessive
enthusiasm for detecting effects of the treatment under study (34–36). Assessments of
eligibility for a clinical trial may be biased toward baseline score inflation when
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investigators have a financial incentive to recruit patients (37). Evidence for baseline score
inflation comes from studies comparing clinician-administered HAM-D data with self-
reported HAM-D scores obtained using interactive voice systems (38–39). These studies
have found that clinician-rated HAM-D scores are significantly greater than self-reported
scores at the time of patient enrollment, while the two assessment methods yield converging
scores following randomization. This suggests that investigators are influenced, perhaps
unconsciously, by the financial and professional returns accruing from an enrolled patient
vs. a screen failure to increase their ratings of baseline depression severity.
Conversely, a response bias in psychological measurement is the systematic tendency of a
subject to respond to questionnaire items on some basis other than what the items were
designed to measure (40). Response bias occurs when respondents choose the response they
perceive to be the most socially desirable or that is favored by the clinicians in a research
study. The term “demand characteristics” has been used to describe cues that make
participants in a research study aware of what results the experimenters hope to find, which
can result in the participants altering their responses to conform to the researchers’
expectations (40). “Hawthorne effects” are a closely related phenomenon whereby subjects
in an experiment improve or modify the aspect of their behavior under study simply by
virtue of knowing the behavior is being measured (40). Response bias can be more
problematic in antidepressant clinical trials compared to studies of non-psychiatric disorders
due to the inherently subjective nature of rating illness severity based upon the verbal
reports of patients.
Methods of minimizing measurement factors in clinical trials
Effect sizes for antidepressant medications relative to placebo are calculated by dividing the
quotient of the mean improvement in the medication group and the mean improvement in
the placebo group by the pooled standard deviation of the sample ([ImprovementMedication −
ImprovementPlacebo]/Standard Deviation). As measurement error (and standard deviation)
increases, the calculated effect size for antidepressant medication decreases, and the
likelihood of detecting a statistically significant benefit of medication over placebo
decreases. Thus, it is important for signal detection in antidepressant clinical trials to reduce
measurement error. The primary method to reduce measurement error in antidepressant
clinical trials is to institute a comprehensive and ongoing rater training program, in which
inter-rater reliability is carefully measured and maintained at a minimum level.
Unfortunately, information regarding inter-rater reliability in antidepressant clinical trials is
almost never provided in published reports (41).
The problems posed by regression to the mean and rater bias (particularly baseline score
inflation) in antidepressant clinical trials have been approached in several ways (42). One
strategy involves specifying a minimum depression severity score required for enrollment
into the study but then a priori setting a higher score threshold required for inclusion of the
subject in the data analysis. Another technique is to blind raters at individual study sites to
the timing of baseline assessment so that they are unaware which ratings will be used to
ascertain patient eligibility for the study. Finally, many investigators now utilize two
separate depression rating scales for clinical trials: one measure to determine subject
eligibility, and a different scale to serve as the primary outcome measure in analyses.
A variant of these strategies is to utilize centralized raters to perform the screening and
outcome measures in clinical trials (42). Using centralized raters provides investigators with
access to a group of highly trained raters that are not often available to individual study sites.
Centralized raters are less prone to bias by virtue of their off-site location and blinding to
study entry criteria, patient phase of treatment, and treatment assignment. Thus, the use of
centralized ratings may improve inter-rater reliability, relieve pressure to enroll patients,
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reduce biases toward baseline score inflation and observing improvement, and eliminate
effects of repeated assessments by the same clinician. A relative disadvantage of using
centralized raters is the necessity of assessing patients remotely via video conference or
telephone rather than having a face to face interview.
Natural History Factors Contributing to Placebo Response
Given the ethical difficulties associated with following the untreated course of depression,
few prospective non-intervention studies using modern diagnostic criteria exist that may be
used to estimate the magnitude of spontaneous improvement that can be expected in acute
depressive episodes (43). Alternate sources of information about the natural course of
depressive disorders are psychotherapy studies utilizing a “wait-list” control group as a
means of determining whether psychotherapy has an effect on depression beyond the
passage of time. A recent meta-analysis of acute symptom change in wait-list control
conditions found that individuals with Major Depressive Disorder experience an average
improvement of 4 HAM-D points (Cohen’s d effect size = 0.5) over a mean follow up
duration of 10 weeks (44). For comparison, meta-analyses of medication and placebo
response in antidepressant clinical trials report standardized effect sizes of approximately
1.5 for medication conditions and 1.2 for placebo conditions (10). Thus, patients in wait-list
control conditions experience approximately 33% of the improvement occurring with
medication treatment and 40% of the improvement seen with placebo administration.
It is intriguing to speculate that natural history factors may be playing an increased role in
antidepressant clinical trials over time as the population of patients enrolling in research
studies changes. Most research participants in the 1960s and 1970s were recruited from
inpatient psychiatric units, while current participants are symptomatic volunteers responding
to advertisements (45). Studies are needed to compare the baseline characteristics, treatment
response, and attrition rates of self-referred depressed patients compared to those who
respond to advertisements. Natural history factors may be more important among the latter
population, with the symptoms experienced by advertisement respondents being more
variable and transient, resulting in increased placebo response rates, compared to self-
referred patients.
It may be possible to mitigate natural history factors by requiring longer durations of current
illness for inclusion in antidepressant trials, but the spontaneous fluctuation of depression
severity is less subject to investigator control than measurement factors. Epidemiologic
studies show that patients with Major Depressive Disorder typically experience symptoms
for several months prior to seeking treatment (46). Patients are most likely to seek treatment
during periods of increased stress or symptomatic worsening, so those who enroll in a
clinical trial at this time of peak symptomatology may experience natural waning of
symptoms or alleviation in the precipitating stressors irrespective of the treatment they are
provided.
Patient Characteristics Moderating Placebo Response
Expectancy-based placebo effects are dependent upon intact cognition in order to generate
placebo response (47), and a physiologic pathway must exist by which expectancy can
influence the illness (i.e., minimal placebo effects are observed on tumor regression in
metastatic cancer). However, among cognitively intact patients with depression, research has
failed to identify consistent characteristics of patients likely to respond to placebo, giving
rise to the term “the elusive placebo reactor” as early as the 1960s (48). Patient
characteristics such as neuroticism, suggestibility, introversion, intelligence, and self-esteem
have not been found to have significant associations with response to placebo (49). This has
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led many to reject the hypothesis that certain people respond to placebos while others do
not, and instead the consensus view arose that most individuals appear capable of being
influenced by placebo effects under the appropriate conditions (50).
While evidence for patient characteristics influencing placebo response has been limited,
features of the depressive illness being treated appear to influence the magnitude of placebo
response observed in an antidepressant clinical trial. One of the most replicated findings in
recent years has been that placebo response decreases with increasing severity of baseline
depression scores. Both Kirsch et al (2008) and Fournier et al (2010) found that placebo
response significantly declined as baseline HAM-D increased (particularly as it exceeded a
score of 25) (51–52). Other studies suggest that patients suffering from Major Depressive
Disorder with Psychotic Features (53) and Recurrent Major Depressive Disorder (54) have
decreased rates of placebo response, as do elderly depressed patients with early-onset (prior
to age 60) depression (55).
Relationship of Placebo Response to Medication Response in
Antidepressant Clinical Trials
A fascinating and important question in pharmacologic treatments is how to conceptualize
the contribution of placebo response to medication response. “Medication response” denotes
the change in symptoms occurring during a clinical trial in patients randomized to receive
medication. In contrast, the “medication effect” is the specific physiologic effect of the
medication being studied on the target disorder (e.g., the effect of serotonin reuptake
inhibition on Major Depressive Disorder). By extension from Figure 1, medication response
represents a combination of the specific medication effect with the previously described
sources of placebo response (i.e., expectancy-based placebo effects, effects of the
therapeutic setting, measurement factors, and natural history factors). The simplest and most
common way to understand the nature of this combination is to assume that medication
effects are additive with placebo response (i.e., placebo response is the same in the
medication and placebo groups). In other words, if the observed placebo response in a
clinical trial is 30% and the observed medication response is 50%, then the specific effects
of the medication account for 50%–30% = 20% of the observed response. If the specific
effects of medication are relatively constant between similar patient samples, differences in
observed medication response between different types of antidepressant studies (e.g.,
placebo-controlled, comparator, open) would presumably be caused by differences in
expectancy-based placebo effects and other non-pharmacologic factors.
The logic of clinical trials and their application to clinical treatment are based upon this
“assumption of additivity” (56): medications are approved for use after demonstration of a
significant difference compared to placebo, and the “number needed to treat” is calculated
relative to placebo response. It is therefore surprising that there exists little to no evidence in
the pharmacologic treatment of Major Depressive Disorder to prove that medication effects
and the placebo response are additive. Equally possible is that all of the observed medication
response is caused by the specific medication effect without any contribution from placebo
response, in which case the medication effect would be substantially larger than that
calculated based on additivity. Alternately, the presence of interactions between medication
effects and sources of placebo response could result in the true contribution of medication
effects to medication response being smaller than previously thought. For example,
experiencing side effects known to be caused by the medication under study may “unblind”
patients during a clinical trial, increasing their expectancy of improvement and leading to
larger expectancy-based placebo effects.
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To answer the question of how medication effects combine with sources of placebo
response, it is necessary to conduct studies designed to test the assumption of additivity in
antidepressant clinical trials. Kirsch (1990) has suggested that a modified form of the
balanced placebo design may serve this function by randomizing a sample of patients with
Major Depressive Disorder to be told they are receiving active medication vs. told they are
receiving placebo (57). Each group is then further randomized to actually receive medication
or placebo, allowing one to estimate the true drug effect by comparing response in the “Told
Placebo/Receive Medication” and “Told Placebo/Receive Placebo” groups. Utilizing an
active placebo with this study design would make it possible to control for unblinding by
side effects as well. While this study design represents a cogent approach to disentangling
medication effects from placebo response, ethical concerns with the temporary deception of
depressed patients entailed in the balanced placebo design have precluded its use to date.
Alternatively, new statistical approaches have been developed to more accurately estimate
the causal effect of medication on depression using standard clinical trial data sets. Muthen
and Brown (2009) conceptually delimit four types of patients in a randomized controlled
trial: those who would not respond to medication or placebo (‘Never responders’), those
who would respond to both medication and placebo (‘Always responders’), those who
would respond to medication but not placebo (‘Medication only responders’), and those who
would respond to placebo but not medication (‘Placebo only responders’) (58). ‘Drug only
responders’ are the group of interest to pharmacologic researchers, since these subjects are
assumed to be experiencing a true medication effect. ‘Placebo only responders’ result from
subjects experiencing adverse effects to medication, and they are assumed to be few in
number. Applying growth mixture modeling with maximum-likelihood estimation to an
antidepressant clinical trial data set, the authors report a method resulting in larger effect
size estimates for ‘Drug only responders’ compared to conventional analyses. While this
approach appears promising, it is not clear that it accounts for the possibility of interactions
between medication effects and placebo response described above.
It appears likely that the specific effect of medication is at least partially additive with
placebo response, though its precise magnitude cannot be determined without knowing
whether there are significant medication effect x placebo response interactions. The
considerations discussed in this section make clearer how rising placebo response makes it
difficult to demonstrate statistically significant benefits of medications over placebo. First,
rising placebo response leads to decreased medication-placebo differences (3), because the
group of patients who do not respond to medication or placebo (i.e., ‘Never responders’)
place a ceiling on medication response in an antidepressant clinical trial. An increase in
placebo response thereby causes a corresponding decrease in the medication-placebo
difference. Second, investigators have attempted to compensate for the decreasing effect
sizes observed for antidepressant medication by employing multiple study sites to obtain
larger sample sizes. The increased measurement error associated with multicenter clinical
trials leads to decreased effect sizes for medication and often offsets the benefits of greater
sample size.
Implications for the Antidepressant-Placebo Controversy
Media coverage of placebo response has been used as a platform for critiques of the
pharmaceutical industry and a stalking horse for questioning the efficacy of antidepressants.
For example, a recent “60 Minutes” report on CBS titled “Treating Depression: Is There a
Placebo Effect?” (59) focused on a meta-analysis of 35 clinical trials of 4 antidepressants for
Major Depressive Disorder published in 2008 (52). Standardized mean effect sizes were
calculated for the pre-post symptom change observed in participants randomized to
antidepressant medication and placebo, resulting in an effect size of 1.24 for medication and
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0.92 for placebo (p < 0.001). However, when standardized mean differences between drug
and placebo were examined as a function of initial depression severity, the difference in
mean effect size exceeded the threshold for a “clinically significant” difference (defined as
an effect size difference of 0.5) only among patients with a baseline HAM-D score ≥ 28.
Criticism of this meta-analysis has focused on its relatively small and selective sample of the
available studies. In addition, comparing overall mean differences between drug and placebo
groups does not account for different trajectories of treatment response (60) and is relatively
insensitive to large and significant changes experienced by subgroups of the sample (61).
However, other analyses using different methods and samples have reported similar
findings, suggesting that the mean HAM-D difference between antidepressant medication
and placebo may be modest for patients with milder depression (51).
A frequent conclusion drawn from these studies by the media as well as the public is that
“antidepressants do not work better than no treatment at all”. This conclusion represents an
incorrect interpretation of the data, which may have the dangerous public health
consequence of dissuading patients with depression from accessing treatment. First, patients
receiving antidepressants in clinical trials improve a great deal—the standardized mean
effect size of 1.24 for antidepressant treatment is large. Second, being assigned to placebo in
an antidepressant trial is far from “no treatment,” since it entails intensive contact with
health care staff that greatly exceeds what is delivered in standard community treatment.
More accurately, the above meta-analytic findings suggest that eliciting placebo effects and
providing a therapeutic setting are powerful treatments for mild to moderate depression, and
the specific effects of antidepressant medication result in small additional decreases in
HAM-D scores over these interventions.
In order to benefit from placebo effects and a therapeutic setting, patients must receive some
type of treatment. Most psychiatrists would agree that deception and the covert prescription
of placebo are unethical for patients with depression. The question facing clinicians then
becomes: of currently available treatments, what is the optimal way to elicit placebo effects
and provide a therapeutic setting for patients with milder forms of depression? Some policy-
makers have advised utilizing psychotherapy as the initial treatment approach, presumably
as a means of eliciting placebo responses without the cost and potential side effect burden
associated with antidepressants (62). While this may be reasonable for some patients, we
would caution against blanket recommendations in favor of a thoughtful consideration of the
risks and benefits of medication and psychotherapy for each individual. Psychotherapy is not
always cheaper than antidepressant medication—analyses of their comparative cost-
effectiveness have mostly shown minimal differences (63), and in some populations
psychotherapy may be more expensive than medication as a treatment for depression (64).
Like medication, psychotherapy may be associated with significant side effects, such as
worsening symptoms and the fostering of dependence and regression (65). Finally, both
psychotherapy and antidepressant medication may have therapeutic effects beyond merely
decreasing HAM-D scores that should be considered. For example, treatment with
antidepressant medication has been shown to result in salutary personality change (i.e.,
decreased neuroticism) compared to cognitive therapy or placebo (66).
Future Directions: Developing Strategies for Maximizing and Minimizing
Placebo Response in the Treatment of Major Depressive Disorder
Valid evaluation of putative antidepressant agents requires that placebo response be
minimized in the drug development setting, while the best care for patients with depression
may involve maximizing placebo response in clinical treatments. Data presented in this
review suggest that the next generation of research aimed at reducing placebo response
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should focus on limiting patient expectancy and the intensity of therapeutic contact in
antidepressant clinical trials (see Table 2). More research is needed to elucidate how
antidepressant study design, the content and process of informed consent discussions, and
clinician attitudes affect patient expectancy and treatment outcome. Designs in which
patients have a higher probability of receiving placebo (i.e., 50%) may be preferable to
designs randomizing patients to multiple active treatment arms and placebo. In terms of
therapeutic contact intensity, future studies should examine whether clinical trials could be
made more efficient and generalizable to clinical practice by reducing the amount of contact
with health care staff to levels resembling treatment in the community. However, it must be
determined whether acceptable attrition rates and patient safety can be maintained while
reducing placebo response.
Conversely, the optimal strategy in clinical practice may be to combine active medication
with a presentation and level of therapeutic contact that enhances placebo effects, leading to
greater medication response. Updated clinical management techniques may involve
educating patients about the effectiveness of the prescribed medication and utilizing a
confident and enthusiastic interpersonal style. While efforts to identify the “elusive placebo
reactor” have historically been unsuccessful, it is possible that demographic or clinical
characteristics related to the formulation of treatment expectancies or patients’ experience of
the treatment setting may be associated with placebo response. Identifying patients likely to
respond to these factors may permit them to be targeted with enhanced interventions. In
developing these interventions, it may be useful to employ more “objective” measures of
treatment response such as neuroimaging in order to ensure these interventions actually
improve depression rather than simply introduce response biases.
A limitation of this review is that there is not sufficient space to address the neurobiology of
placebo effects. Functional magnetic resonance imaging (fMRI) studies of expectancy-based
placebo effects have provided converging evidence suggesting that the brain areas
associated with generating and maintaining expectancies comprise prefrontal cortex
subregions, orbitofrontal cortex, and the rostral anterior cingulate cortex (67). In treatment
for depression, response to placebo has been associated with regionally-specific alterations
in brain metabolism that represent a sub-set of the areas associated with response to
antidepressant medication (68). Research aimed at further elucidating the biological
pathways that lead to placebo effects is underway, and results of these studies are likely to
yield information about the pathophysiology of Major Depressive Disorder and the
mechanisms of action of antidepressant treatments.
In summary, placebo response in antidepressant clinical trials is a fascinating and complex
phenomenon worthy of scientific investigation. Investigating the mechanisms of placebo
effects has the potential to illuminate the pathophysiology of depression as well as the active
ingredients of clinical trials. The public health benefit of research on placebo effects is that
knowledge of their mechanisms may permit the development of strategies to modulate their
magnitude depending on the context, thereby improving signal detection in drug
development studies and increasing antidepressant response in clinical treatment.
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